We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

188 hedge funds and large institutions have $2.05B invested in Protagonist Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 63 increasing their positions, 68 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

18% more capital invested

Capital invested by funds: $1.73B → $2.05B (+$312M)

15% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 26

2% more funds holding

Funds holding: 185 → 188 (+3)

7% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 68

2.2% less ownership

Funds ownership: 102.91% → 100.71% (-2.2%)

87% less call options, than puts

Call options by funds: $956K | Put options by funds: $7.56M

Holders
188
Holders Change
+3
Holders Change %
+1.62%
% of All Funds
2.72%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
30
Increased
63
Reduced
68
Closed
26
Calls
$956K
Puts
$7.56M
Net Calls
-$6.61M
Net Calls Change
-$894K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$26.8M
2
JFG
Jefferies Financial Group
New York
+$25.2M
3
ACM
ADAR1 Capital Management
Texas
+$24M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$11.5M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$11.4M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$44.9M
2
State Street
State Street
Massachusetts
-$34.9M
3
BI
BVF Inc
California
-$12.8M
4
Marshall Wace
Marshall Wace
United Kingdom
-$11.9M
5
CAC
Cowen and Company
New York
-$11M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$202M +$2.98M +101,800 +2%
BlackRock
2
BlackRock
New York
$200M +$5.52M +188,627 +3%
RI
3
RTW Investments
New York
$183M -$853K -29,110 -0.5%
BI
4
BVF Inc
California
$115M -$12.8M -436,700 -12%
Vanguard Group
5
Vanguard Group
Pennsylvania
$112M +$1.48M +50,502 +2%
JJ
6
Johnson & Johnson
New Jersey
$84.9M – – –
State Street
7
State Street
Massachusetts
$72.2M -$34.9M -1,190,161 -36%
JFG
8
Jefferies Financial Group
New York
$70.7M +$25.2M +860,000 +73%
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$69.3M -$6.37M -217,526 -10%
ACM
10
ADAR1 Capital Management
Texas
$55.6M +$24M +818,277 +104%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$47.5M +$2.27M +77,430 +6%
PA
12
Perceptive Advisors
New York
$44M +$8.04M +274,412 +28%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$41.9M +$11.4M +390,246 +48%
CAC
14
Cowen and Company
New York
$41M -$11M -375,368 -24%
Millennium Management
15
Millennium Management
New York
$33.2M +$26.8M +915,418 +2,136%
FFM
16
Fairmount Funds Management
Pennsylvania
$32.3M – – –
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$31.5M -$8.5M -290,168 -24%
Deutsche Bank
18
Deutsche Bank
Germany
$31.5M -$72K -2,458 -0.3%
WP
19
Woodline Partners
California
$28.5M +$5.42M +185,217 +29%
KCM
20
Kynam Capital Management
New Jersey
$27.7M -$10.1M -344,242 -30%
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$21.3M -$5.13M -175,172 -22%
6CM
22
683 Capital Management
New York
$20.9M -$2.8M -95,551 -14%
Goldman Sachs
23
Goldman Sachs
New York
$20.5M +$1.92M +65,721 +13%
Marshall Wace
24
Marshall Wace
United Kingdom
$19.8M -$11.9M -404,716 -41%
DCM
25
Driehaus Capital Management
Illinois
$19.3M -$108K -3,695 -0.7%
1
2 3 4 5

PTGX Hedge Fund Activity: Q2 2024 in Review

188 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2024, worth a combined $2.05B — up 18% from $1.73B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new PTGX positions and 26 closed out — a net gain of 4 holders — while 63 added to existing stakes and 68 trimmed.

The largest buyer was Millennium Management, adding an estimated $26.8M. The largest seller was Morgan Stanley, cutting an estimated $44.9M.

  • 188 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2024, up from 185 in Q1 2024.
  • Funds reported $2.05B of Protagonist Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
  • 30 funds opened new Protagonist Therapeutics positions in Q2 2024 and 26 closed out, a net change of +4 holders.
  • The largest Protagonist Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $26.8M added.
  • The largest Protagonist Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $44.9M sold.

Based on aggregated 13F filings for Q2 2024.